Skip to main content

Table 1 Baseline patient characteristics and underlying malignancy

From: Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial

Age in years (range) 60.5 (30 - 81)
Gender
   Male 56 (64%)
   Female 31 (36%)
Baseline serum creatinine concentration in mg/dl (± SEM) 0.81 (± 0.28)
Arterial hypertension 21 (24%)
Concomitant nephrotoxic/volume depleting or blood pressure lowering medication
- NSAIDs 18 (21%)  
- Loop diuretics 14 (16%)  
- Thiazides 8 (9%)  
- ACE inhibitor 6 (7%)  
- AT2 blocker 4 (5%)  
- Aldosterone antagonists 2 (2%)  
Preceding chemotherapy 45 (52%)  
Liver metastasis 45 (52%)  
  Group A (treated with capezitabine, rofecoxib and pioglitazone) Group B (treated with trofosfamid, rofecoxib and pioglitazone)
Melanoma   16
Gastric carcinoma 13  
Colorectal carcinoma 12  
Renal cell carcinoma 9  
Hepatic carcinoma/Klatskin 7  
Sarcoma   5
Pulmonary adenocarcinoma/SCLC   3
Pancreatic cancer 3  
Urothelium carcinoma 3  
Gall bladder carcinoma 3  
Breast cancer   2
Histiozytosis X   2
Hodgkin/Non-Hodgkin-Lymphoma   2
Ovarial carcinoma   2
TNE   2
Chronic lymphatic leukemia   1
Cervix carcinoma   1
  1. SCLC = small cell lung cancer; TNE = throat nose ear